Endo International, a generics and specialty branded pharmaceuticals company, has announced that Paul V. Campanelli, President and Chief Executive Officer (CEO) has notified the company’s Board of Directors of his intention to retire, and the Endo Board is implementing its CEO succession plan. 

Mr. Campanelli has been appointed Chairman of the Board, effective immediately (as of an announcement on November 4, 2019) and will also continue to serve as President and CEO until his successor is appointed.  Roger Kimmel, who has served as Chairman of the Board, has been appointed Senior Independent Director.  Mr. Kimmel replaces Dr. Sharad Mansukani, who is resigning from the Board due to other commitments, including his recent appointment as chairman of the board of another company.

Endo’s Board is launching a process to identify Mr. Campanelli’s successor, and Endo says that Mr. Campanelli will be actively involved in that process and will help facilitate a smooth transition.  In addition, he will continue to serve as Chairman of the Board following the appointment of his successor.

Source: Endo International